The European Medicines Agency (EMA) has issued a marketing authorisation valid throughout the EU for a vaccine against a new type of haemorrhagic disease virus.
Rabbit haemorrhagic disease virus type two (RHDV2) has affected rabbits in the UK and the Eravac vaccine, produced by Hipra Laboratories, is indicated for the active immunisation of fattening rabbits from the age of 30 days to reduce mortality caused by the disease.
Solution to a problem
If Eravac is not available or suitable, however, the VMD has said it will accept applications to import unauthorised medicines into the UK to treat RHDV2. Vaccines against RHDV2 authorised in other EU countries, meanwhile, which have previously been imported, include Filavac VHD K C+V from France and Novarvilap from Spain.
The VMD stated: “No information is available on the safety and efficacy of these vaccines for pet rabbit breeds, including when they are used at the same time as other vaccines (for example, classical RHDV or myxomatosis vaccines).
“Vets should use their clinical judgement in individual cases to decide the most suitable vaccination protocol. The vet should contact the vaccine manufacturer directly for further information.”
Further information on the authorisation is available on the EMA website.